IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, previously announced on June 29 the successful capital increase of €10 million through a private placement. As a result of this capital increase, the denominator or issued shares with voting rights changed from 18,622,327 to 25,513,440. Each shareholder of the Company is entitled to one vote per share.
